NovaMedica to market Ferrings innovative GI products in Russia

03 June 2015

The PharmaLetter

Privately-held Switzerland-headquartered Ferring Pharmaceuticals has signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.

“We are glad to collaborate with NovaMedica and believe that this company is the right choice because of its long-term strategy targeted at bringing innovative gastroenterological products to Russian patients”

The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices.

Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more